A Randomized, Single-center, Open-label, 5-way Crossover, Single-dose Bioavailability/Bioequivalence Comparison of Brivaracetam Oral Tablets (10 mg, 50 mg,75 mg, and 100 mg) and Brivaracetam Intravenous Bolus Injection (100 mg) in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2016
At a glance
- Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
- Indications Epilepsy; Pain
- Focus Pharmacokinetics
- Sponsors UCB Pharma SA
- 26 Jun 2016 Results published in the Epilepsia
- 21 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.